Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 25 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Balloon-based endoscopic ablation can eliminate Barrett's

Circumferential ablation of Barrett's using balloon-based endoscopic radiofrequency eliminates the disease in the majority of patients, shows February's Gastrointestinal Endoscopy.

News image

fiogf49gjkf04

Dr Virender Sharma and colleagues from Arizona assessed the dose-response, safety, and efficacy of circumferential endoscopic ablation of Barrett's esophagus.

The researchers used an endoscopic balloon-based ablation device that delivered a pre-set amount of energy density to Barrett's tissue.

The researchers conducted the study in 2 serial phases at 8 centers between 2003 and 2005.

The first phase included the dosimetry phase, which evaluated the dose-response and the safety of delivering 6 to 12 J/cm2 in 32 patients.

The second was the effectiveness phase, and used 10 J/cm2 in 70 patients.

There was a complete response for Barrett's in 70% of patients
Gastrointestinal Endoscopy

The procedures were delivered twice for all patients, followed by EGD with biopsies at 1, 3, 6, and 12 months.

The researcher performed a second ablation procedure if Barrett' esophagus was present at 1 or 3 months.

Patients received esomeprazole 40 mg twice a day for 1 month after ablation, and 40 mg every day thereafter.

The team quantified postablation symptoms by using a 14-day symptom diary.

The researchers defined a complete response as all biopsy specimens negative for Barrett's esophagus at 12 months.

Patients were 18 to 75 years of age, with a diagnosis of Barrett's esophagus and without dysplasia.

The patients had histopathology reconfirmation of the diagnosis within 6 months of enrollment.

Median symptom scores returned to a score of 0 of 100 by day 3 in the dosimetry phase.

The team observed no dose-related serious adverse events.

The outcomes at 1 and 3 months permitted the selection of 10 J/cm2 for the subsequent effectiveness phase of the study.

During the effectiveness phase, the team noted that median symptom scores returned to a score of 0 of 100 by day 4.

At 12 months, the researchers achieved a complete response for Barrett's esophagus in 70% of patients.

The researchers found no strictures, and no buried glandular mucosa in either study phase.

Dr Sharma's team concludes, “Circumferential ablation of nondysplastic Barrett's esophagus by using this balloon-based ablation device can be performed with no subsequent strictures or buried glands.

“This method completely eliminates Barrett's esophagus in 70% of patients at 1-year follow-up.”

Gastrointest Endoscopy 2007: 65(2): 185-95
07 February 2007

Go to top of page Email this page Email this page to a colleague

 23 February 2018 
Patients on antithrombotic agents undergoing emergency and elective endoscopy
 23 February 2018 
Heavy metals on a gluten-free diet
 23 February 2018 
MRI and NAFLD
 22 February 2018 
Outcomes with Crohn’s after infliximab withdrawal
 22 February 2018 
Elderly onset of IBD

 22 February 2018 
Autophagy enhancers
 21 February 2018 
Management of hemorrhoids in the USA
 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us